CD20, an antigen expressed by various B and T cells, is an attractive therapeutic target in various cancers and autoimmune conditions.A244195, A244200, A244205 Monoclonal antibodies for B cell depletion rely on their binding affinity and ability to clear bound cells through mechanisms such as antibody-dependent cellular cytotoxicity (ADCC), mediated by interactions between an antibody and Fc? receptors on natural killer cells or macrophages.A244210 Ublituximab is a chimeric anti-CD20 IgG1? antibody produced in the rat YB2/0 cell line to target a unique epitope and enhance ADCC compared to other approved anti-CD20 antibodies such as rituximab, ofatumumab, obinutuzumab, and ocrelizumab.A244210, A244215,A241045
Ublituximab was initially developed by LFB Group but was licensed to TG Therapeutics in 2012. It has been investigated for use in numerous B cell-dependent conditions, including chronic lymphocytic leukemia, non-Hodgkin's lymphoma, and relapsing multiple sclerosis.A241045 In December 2022, ublituximab was approved by the US FDA for the treatment of relapsing forms of multiple sclerosis, becoming the first and only anti-CD20 monoclonal antibody for multiple sclerosis allowing for administration in a one-hour infusion twice-a-year following the starting dose.L44508 The next year, June 2023, ublituximab was also approved by the EMA for the treatment of relapsing forms of multiple sclerosis in adult patients.L47486
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Ublituximab. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Ublituximab. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Ublituximab. |
| Estrone | Estrone may increase the thrombogenic activities of Ublituximab. |
| Estradiol | Estradiol may increase the thrombogenic activities of Ublituximab. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Ublituximab. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Ublituximab. |
| Mestranol | Mestranol may increase the thrombogenic activities of Ublituximab. |
| Estriol | Estriol may increase the thrombogenic activities of Ublituximab. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Ublituximab. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Ublituximab. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Ublituximab. |
| Tibolone | Tibolone may increase the thrombogenic activities of Ublituximab. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Ublituximab. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Ublituximab. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Ublituximab. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Ublituximab. |
| Zeranol | Zeranol may increase the thrombogenic activities of Ublituximab. |
| Equol | Equol may increase the thrombogenic activities of Ublituximab. |
| Promestriene | Promestriene may increase the thrombogenic activities of Ublituximab. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Ublituximab. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Ublituximab. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Ublituximab. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Ublituximab. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Ublituximab. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Ublituximab. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Ublituximab. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Ublituximab. |
| Formononetin | Formononetin may increase the thrombogenic activities of Ublituximab. |
| Estetrol | Estetrol may increase the thrombogenic activities of Ublituximab. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Ublituximab. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Ublituximab. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Ublituximab. |
| Adalimumab | The risk or severity of infection can be increased when Ublituximab is combined with Adalimumab. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Ublituximab. |
| Gemtuzumab ozogamicin | The risk or severity of infection can be increased when Ublituximab is combined with Gemtuzumab ozogamicin. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Ublituximab. |
| Infliximab | The risk or severity of infection can be increased when Ublituximab is combined with Infliximab. |
| Trastuzumab | The risk or severity of neutropenia can be increased when Trastuzumab is combined with Ublituximab. |
| Rituximab | The risk or severity of infection can be increased when Ublituximab is combined with Rituximab. |
| Basiliximab | The risk or severity of infection can be increased when Ublituximab is combined with Basiliximab. |
| Muromonab | The risk or severity of infection can be increased when Ublituximab is combined with Muromonab. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Ublituximab. |
| Ibritumomab tiuxetan | The risk or severity of infection can be increased when Ublituximab is combined with Ibritumomab tiuxetan. |
| Tositumomab | The risk or severity of infection can be increased when Ublituximab is combined with Tositumomab. |
| Alemtuzumab | The risk or severity of infection can be increased when Ublituximab is combined with Alemtuzumab. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Ublituximab. |
| Efalizumab | The risk or severity of infection can be increased when Ublituximab is combined with Efalizumab. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of infection can be increased when Ublituximab is combined with Antithymocyte immunoglobulin (rabbit). |
| Natalizumab | The risk or severity of immunosuppression can be increased when Ublituximab is combined with Natalizumab. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Ublituximab. |
| Daclizumab | The risk or severity of infection can be increased when Ublituximab is combined with Daclizumab. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ublituximab. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Ublituximab. |
| Eculizumab | The risk or severity of infection can be increased when Ublituximab is combined with Eculizumab. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with Ublituximab. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with Ublituximab. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with Ublituximab. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with Ublituximab. |
| Afelimomab | The risk or severity of infection can be increased when Ublituximab is combined with Afelimomab. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with Ublituximab. |
| Bectumomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Ublituximab. |
| Oregovomab | The risk or severity of adverse effects can be increased when Oregovomab is combined with Ublituximab. |
| IGN311 | The risk or severity of adverse effects can be increased when IGN311 is combined with Ublituximab. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Ublituximab. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Ublituximab. |
| Matuzumab | The risk or severity of adverse effects can be increased when Matuzumab is combined with Ublituximab. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Ublituximab. |
| Bavituximab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Ublituximab. |
| CR002 | The risk or severity of adverse effects can be increased when CR002 is combined with Ublituximab. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Ublituximab. |
| Girentuximab | The risk or severity of adverse effects can be increased when Girentuximab is combined with Ublituximab. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Ublituximab. |
| XTL-001 | The risk or severity of adverse effects can be increased when XTL-001 is combined with Ublituximab. |
| NAV 1800 | The risk or severity of adverse effects can be increased when NAV 1800 is combined with Ublituximab. |
| Briakinumab | The risk or severity of infection can be increased when Ublituximab is combined with Briakinumab. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with Ublituximab. |
| AMG 108 | The risk or severity of adverse effects can be increased when AMG 108 is combined with Ublituximab. |
| Iratumumab | The risk or severity of adverse effects can be increased when Iratumumab is combined with Ublituximab. |
| Enokizumab | The risk or severity of adverse effects can be increased when Enokizumab is combined with Ublituximab. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Ramucirumab is combined with Ublituximab. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Farletuzumab is combined with Ublituximab. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Veltuzumab is combined with Ublituximab. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Ustekinumab is combined with Ublituximab. |
| Trastuzumab emtansine | The risk or severity of infection can be increased when Ublituximab is combined with Trastuzumab emtansine. |
| PRO-542 | The risk or severity of adverse effects can be increased when PRO-542 is combined with Ublituximab. |
| TNX-901 | The risk or severity of adverse effects can be increased when TNX-901 is combined with Ublituximab. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Ublituximab. |
| RI 624 | The risk or severity of adverse effects can be increased when RI 624 is combined with Ublituximab. |
| Stamulumab | The risk or severity of adverse effects can be increased when MYO-029 is combined with Ublituximab. |
| CT-011 | The risk or severity of adverse effects can be increased when CT-011 is combined with Ublituximab. |
| Leronlimab | The risk or severity of adverse effects can be increased when Leronlimab is combined with Ublituximab. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Ublituximab. |
| Olaratumab | The risk or severity of adverse effects can be increased when Olaratumab is combined with Ublituximab. |
| IPH 2101 | The risk or severity of adverse effects can be increased when IPH 2101 is combined with Ublituximab. |
| TB-402 | The risk or severity of adverse effects can be increased when TB-402 is combined with Ublituximab. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Ublituximab. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Ublituximab. |
| Eldelumab | The risk or severity of adverse effects can be increased when Eldelumab is combined with Ublituximab. |
| Lumiliximab | The risk or severity of adverse effects can be increased when Lumiliximab is combined with Ublituximab. |